Zentalis Pharmaceuticals, Inc. (ZNTL)

Market Cap	253.52M
Revenue (ttm)	40.56M
Net Income (ttm)	-218.96M
Shares Out	71.01M
EPS (ttm)	-3.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,296,751
Open	4.220
Previous Close	4.190
Day's Range	3.435 - 4.220
52-Week Range	3.435 - 29.030
Beta	1.83
Analysts	Buy
Price Target	13.14 (+268.07%)
Earnings Date	Aug 7, 2024

About ZNTL

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 3, 2020
• Employees: 124
• Stock Exchange: NASDAQ
• Ticker Symbol: ZNTL

Analyst Forecast

According to 7 analysts, the average rating for ZNTL stock is "Buy." The 12-month stock price forecast is $13.14, which is an increase of 268.07% from the latest price.

Price Target

$13.14

(268.07% upside)

Analyst Consensus: Buy